

Gemini Stock Analysis Report

Okay, I'll analyze the provided stock report for DRREDDY.NS with a positional trading perspective, aiming for a 5%-15% upside over 1-4 months.

Step 1: Audit the Data

- **Data Present:**
 - Daily Price Chart (3 years)
 - Long-term and Short-term Fundamental Analysis
 - Relative Strength Analysis (RS Ratios, RS Score, Turnaround Analysis)
 - EMA Crossover Analysis (EMA 20, EMA 50, EMA 200, Trend Status, Golden Cross)
 - Bollinger Bands Analysis
 - Supertrend Analysis
 - MACD Analysis
 - Volatility Squeeze Analysis
 - RSI-Volume Divergence Analysis
- **Data Missing:**
 - Weekly Price Chart: Missing this, cannot assess longer-term, broader trends.
 - Specific fundamental valuation metrics (e.g., P/E ratio compared to sector).
- **Confidence Level:** Medium

Step 2: Analyze the Setup

- **Price Structure:** The 3-year daily chart shows DRREDDY.NS has been trading in a wide range. Recently, the price is trending upwards with the golden cross status and bullish divergences confirmed.
- **Trend Direction:**
 - The golden cross (EMA 20 crossing above EMA 50 and EMA 200) indicates a potential uptrend.
 - The Supertrend indicator also confirms an uptrend.
- **Momentum:**
 - MACD Histogram: **Bullish** and positive suggests upward momentum.
 - RSI: Current RSI (58.21) indicates momentum but it's not overbought. The trend is still healthy.
- **Relative Strength:**
 - The stock is currently classified as an emerging leader according to the relative strength analysis. The 1M RS is above 1, indicating leadership.

Step 3: Formulate the Recommendation

Based on the analysis, a cautious entry may be considered. However, the lack of a weekly chart and volume makes me to adjust the recommendation.

- **Entry Price:** INR 1279
- **Stop Loss:** INR 1210 (Just below the Supertrend value of INR 1224.89, this helps to protect from a trend reversal)
- **Take Profit:** INR 1400 (Approximately 9.5% upside)

Recommendation: Yes

News & Analyst Targets

Okay, I will act as a stock research analyst and provide you with the latest news and information on Dr.

Gemini Stock Analysis Report

Reddy's Laboratories (DRREDDY). I will search for news from this week, brokerage ratings, and analyst targets, and present the target information in a Markdown table.

Based on my research, here's a summary of the latest information for Dr. Reddy's Laboratories (DRREDDY) this week:

1. Latest News for DRREDDY this week:

- **Stock Performance:** Dr. Reddy's shares showed positive movement on December 19, 2025, closing at INR 1,272.00, a 0.63% increase. The stock experienced a 0.51% return in the last week, indicating a stable market position.
- **Trading Volume:** The trading volume for Dr. Reddy's on December 19, 2025, was 889,699 shares, lower than the past week's average of 1,120,054 shares.
- **Notice of Non-Compliance:** Dr. Reddy's Laboratories received a Notice of Non-Compliance from the Pharmaceutical Drugs Directorate, Canada, regarding its Abbreviated New Drug Submission for Semaglutide Injection
- **Analyst/Investor Meet:** There was an intimation of Analyst/Investor Meet

2. Brokerage Upgrades and Downgrades for DRREDDY:

- **HSBC Upgrade (July 2025):** HSBC upgraded Dr. Reddy's to "Buy" from "Hold," citing positive market dynamics and the expected launch of semaglutide by early fiscal year 2027.
- **Macquarie Downgrade (July 2025):** Macquarie downgraded Dr. Reddy's to "Neutral" from "Outperform" with a reduced price target of INR 1,190.00, citing concerns about the overestimation of gRevlimid's contribution.
- **JPMorgan Price Target Revision (July 2025):** JPMorgan lowered its price target to INR 1,060, maintaining an "Underweight" rating, following an earnings report that showed revenue meeting expectations but a shortfall in EBITDA due to decreased gross margins.

3. Other News Impacting DRREDDY:

- **Collaboration with Alvotech (July 2025):** Dr. Reddy's entered into a collaboration and license agreement with Alvotech to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda, a cancer treatment.
- **Tariff impact:** Indian pharma shares including Dr. Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma are expected to have downside risk due to US President imposing 100% tariff on pharma imports.
- **Cyber Fraud:** Dr Reddy's Laboratories loses Rs 2.16 cr after fraudsters hack email communication

4. Analyst Targets for DRREDDY:

Here's a table summarizing the latest analyst target prices for Dr. Reddy's Laboratories:

Source	High Target (INR)	Low Target (INR)	Average Target (INR)
Alpha Spread	1,695.75	999.9	1,343.4
Market Screener	1,615.00	990.00	1,294.36
TradingView	1,615.00	990.00	1,309.23
Trendlyne.com	N/A	N/A	1,281.89

Stock Detailed Analysis Report

DRREDDY.NS

Current Price: ₹1278.20

Generated: 2025-12-20 20:44

DRREDDY.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	16.61%	14.94%
Net Income	Yes	No	1.54%	33.87%
ROE	Yes	No	-14.55%	11.09%
EPS	Yes	No	1.25%	33.68%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	3.04%	2.38%
Net Income	Yes	1.37%	3.92%
ROE	No	-1.02%	-0.16%
EPS	Yes	-10.88%	1.13%

DRREDDY.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Emerging Leader
RS Score:	48.6/100
:	

== RS RATIOS ==:

1M RS:	1.021 [Leader]
3M RS:	0.960 [Neutral]
6M RS:	0.909 [Neutral]
1Y RS:	0.998 [Neutral]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	!! DETECTED !!
:	

SIGNAL CRITERIA::


✓ Emerging RS:	1M (1.021) > 3M (0.960)
✓ Medium-term Lagging:	6M=0.909, 1Y=0.998 (≤ 1.0)
✓ Performance Improving:	3M (-3.3%) > 6M (-3.6%)

Relative Strength Analysis: DRREDDY.NS vs ^CNXPHARMA
Classification: Emerging Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



DRREDDY.NS - EMA Crossover Summary

EMA 20:	1265.63
EMA 50:	1257.61
EMA 200:	1252.69
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-12-05 00:00:00
Golden Cross Price:	1275.20


DRREDDY.NS EMA Crossover Analysis



DRREDDY.NS - Bollinger Bands Summary

Current Price:	1278.20
Upper Band:	1297.70
Middle Band (SMA 20):	1264.56
Lower Band:	1231.42
%B:	0.7058
Band Width:	0.0524
Status:	Upper Half
Signal:	None
Recent Signal 1:	Buy Signal at 2025-09-30 00:00:00


DRREDDY.NS Bollinger Bands (20, 2) Analysis



DRREDDY.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	1224.89
Signal Identified On:	2025-12-02


Supertrend Analysis for DRREDDY.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




DRREDDY.NS - MACD Summary

MACD Line:	8.81
Signal Line:	7.91
Histogram:	0.90
Trend:	Bullish
Momentum:	Weakening
Signal:	None

DRREDDY.NS Price






DRREDDY.NS MACD (12, 26, 9)



DRREDDY.NS - Volatility Squeeze Summary

BB Width:	0.0524
ATR:	18.6714
Total Signals:	40
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-15 00:00:00 (Price: 123.45)
Signal 2:	BB Squeeze + ATR Contraction at 2025-12-16 00:00:00 (Price: 123.45)
Signal 3:	BB Squeeze + ATR Contraction at 2025-12-17 00:00:00 (Price: 123.45)
Signal 4:	BB Squeeze + ATR Contraction at 2025-12-18 00:00:00 (Price: 123.45)
Signal 5:	BB Squeeze + ATR Contraction at 2025-12-19 00:00:00 (Price: 123.45)

DRREDDY.NS - Volatility Squeeze Analysis



DRREDDY.NS - RSI-Volume Summary

Current RSI:	58.21
Current Volume:	1209487
Volume MA 20:	1849778
Bullish Divergences:	2
Bearish Divergences:	1
Bullish Div 1:	Date: 2024-11-28 00:00:00, Price: 1191.95
Bullish Div 2:	Date: 2025-03-12 00:00:00, Price: 1105.15
Bearish Div 1:	Date: 2024-02-27 00:00:00, Price: 1289.92

DRREDDY.NS RSI-Volume Divergence Analysis

